A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719 125mcg once-daily alone and in combination with GW642444 25mcg once-daily via novel Dry Powder Inhaler (nDPI) in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719 125mcg once-daily alone and in combination with GW642444 25mcg once-daily via novel Dry Powder Inhaler (nDPI) in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Umeclidinium (Primary) ; Umeclidinium/vilanterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Registrational
  • Acronyms COPD-nDPI
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jul 2014 According to a GlaxoSmithKline media release, Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Anoro-Ellipta (umeclidinium/vilanterol) for the relief of various symptoms due to airway obstruction with COPD.
    • 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
    • 24 Aug 2012 Status changed from active, no longer recruiting to completed, as reported in a GlaxoSmithKline and Theravance media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top